Abstract session: NAFLD - Pharmacological therapy

 Metabolism, alcohol and toxicity

Room 3
Abstract session
28 August 2020 11:00 - 12:30


Title Time

Add to Calendar

AS073 VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: Results of 4-week follow-up assessment from a 12-week Phase 2 randomized, placebo-controlled trial
28 August 2020 11:00 - 11:15
AS074 Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: A phase 2 randomized controlled trial (FASCINATE-1)
28 August 2020 11:15 - 11:30
AS075 Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: A secondary analysis of the phase 3 REGENERATE study
28 August 2020 11:30 - 11:45
AS076* Effects of cotadutide on biomarkers of nonalcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study
28 August 2020 11:45 - 12:00
AS077 Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo controlled Phase 2 clinical trial
28 August 2020 12:00 - 12:15
AS078 EDP-305, a non-bile acid Farnesoid X Receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis  in the Phase 2a ARGON-1 study
28 August 2020 12:15 - 12:30